Charles River Laboratories Intl. Inc (CRL) Given Average Recommendation of “Buy” by Brokerages

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have received a consensus rating of “Buy” from the seventeen analysts that are covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $144.85.

A number of analysts have weighed in on CRL shares. Zacks Investment Research cut Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $162.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. SunTrust Banks upped their price target on Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a research report on Thursday, February 14th. Barclays reiterated a “hold” rating and issued a $135.00 price target on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Finally, KeyCorp upped their price target on Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a research report on Monday, March 11th.

In other news, CFO David Ross Smith sold 4,000 shares of the stock in a transaction on Monday, February 25th. The stock was sold at an average price of $145.43, for a total transaction of $581,720.00. Following the sale, the chief financial officer now owns 24,262 shares in the company, valued at $3,528,422.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen D. Chubb sold 4,540 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $141.23, for a total value of $641,184.20. Following the sale, the director now owns 38,868 shares in the company, valued at approximately $5,489,327.64. The disclosure for this sale can be found here. Insiders have sold 35,568 shares of company stock worth $5,020,462 in the last 90 days. Company insiders own 1.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Fort L.P. acquired a new position in shares of Charles River Laboratories Intl. during the fourth quarter valued at $27,000. Tompkins Financial Corp lifted its stake in shares of Charles River Laboratories Intl. by 63.1% during the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 77 shares during the period. Riverview Trust Co acquired a new position in shares of Charles River Laboratories Intl. during the fourth quarter valued at $30,000. Sageworth Trust Co acquired a new position in shares of Charles River Laboratories Intl. during the first quarter valued at $37,000. Finally, Cresset Asset Management LLC acquired a new position in shares of Charles River Laboratories Intl. during the first quarter valued at $47,000. Institutional investors own 93.90% of the company’s stock.

Shares of NYSE CRL traded down $0.06 during trading hours on Friday, reaching $131.61. The stock had a trading volume of 5,774 shares, compared to its average volume of 461,080. Charles River Laboratories Intl. has a twelve month low of $102.96 and a twelve month high of $149.07. The firm has a market capitalization of $6.39 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 1.69 and a beta of 0.99. The company has a current ratio of 1.63, a quick ratio of 1.39 and a debt-to-equity ratio of 1.10.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.38 by $0.02. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The firm had revenue of $604.57 million for the quarter, compared to analysts’ expectations of $587.65 million. During the same period in the prior year, the business posted $1.29 earnings per share. The business’s revenue was up 22.4% compared to the same quarter last year. On average, research analysts anticipate that Charles River Laboratories Intl. will post 6.47 earnings per share for the current fiscal year.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Why do company’s buyback their stock?

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.